Valuation: Lundbeck

Market Cap 4.53TCr 678.15Cr 605.59Cr 564.95Cr 513.19Cr 965.71Cr 66TCr 975.12Cr 6.78TCr 2.65TCr 33TCr 2.55TCr 2.49TCr 1,07300Cr P/E 2026 *
10.2x
P/E 2027 * 9.96x
Enterprise Value 4.93TCr 738.13Cr 659.15Cr 614.91Cr 558.58Cr 1.05TCr 71TCr 1.06TCr 7.38TCr 2.89TCr 36TCr 2.77TCr 2.71TCr 1,16800Cr EV / Sales 2026 *
1.9x
EV / Sales 2027 * 1.73x
Free-Float
30.74%
Yield 2026 *
3.37%
Yield 2027 * 3.03%
1 day+0.92%
1 week+6.43%
Current month+2.69%
1 month+0.80%
3 months+19.48%
6 months+30.90%
Current year+21.13%
1 week 41.85
Extreme 41.85
44.4
1 month 38.75
Extreme 38.75
45
Current year 31.4
Extreme 31.4
45
1 year 31.4
Extreme 31.4
45
3 years 23.3
Extreme 23.3
45
5 years 21.94
Extreme 21.935
45
10 years 21.94
Extreme 21.935
45
Manager TitleAgeSince
Chief Executive Officer 59 01/10/2023
Director of Finance/CFO 49 01/09/2022
Chief Operating Officer 52 -
Director TitleAgeSince
Director/Board Member 67 25/03/2015
Director/Board Member 67 25/03/2015
Director/Board Member 60 20/03/2018
Change 5-day change 1-year change 3-year change Capi.($)
+0.92%+6.43% - - 678.15Cr
-1.61%+1.72%+38.30%+106.93% 1,04300Cr
-0.76%-0.84%+35.21%+62.70% 62TCr
+0.39%+4.81%+17.81%+83.77% 48TCr
-0.29%-0.99%+64.79%+37.06% 35TCr
-2.03%+1.06%+21.08%+42.16% 34TCr
-1.92%-0.29%+10.54%+33.20% 27TCr
-2.36%-1.16%-7.14%+8.68% 24TCr
-1.37%+0.04%+38.29%+52.33% 22TCr
+0.17%-0.27%+24.40%+96.82% 18TCr
Average -0.87%+0.28%+27.03%+58.18% 41.63TCr
Weighted average by Cap. -1.04%+0.60%+30.46%+68.88%

Financials

2026 *2027 *
Net sales 2.59TCr 387.61Cr 346.13Cr 322.9Cr 293.32Cr 551.96Cr 38TCr 557.34Cr 3.88TCr 1.52TCr 19TCr 1.46TCr 1.42TCr 61TCr 2.61TCr 391.06Cr 349.22Cr 325.78Cr 295.93Cr 556.88Cr 38TCr 562.3Cr 3.91TCr 1.53TCr 19TCr 1.47TCr 1.44TCr 62TCr
Net income 456.68Cr 68Cr 61Cr 57Cr 52Cr 97Cr 6.63TCr 98Cr 684.34Cr 267.66Cr 3.37TCr 256.89Cr 251.32Cr 11TCr 461.95Cr 69Cr 62Cr 58Cr 52Cr 99Cr 6.7TCr 100Cr 692.22Cr 270.75Cr 3.41TCr 259.85Cr 254.21Cr 11TCr
Net Debt 400.29Cr 60Cr 54Cr 50Cr 45Cr 85Cr 5.81TCr 86Cr 599.84Cr 234.61Cr 2.95TCr 225.17Cr 220.28Cr 9.49TCr -18Cr -2.72Cr -2.43Cr -2.27Cr -2.06Cr -3.88Cr -263.8Cr -3.92Cr -27Cr -11Cr -134.05Cr -10Cr -10Cr -431.1Cr
Projected Income Statement - Annual - Lundbeck
Logo Lundbeck
H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia. Its product portfolio includes: Cipralex for the treatment of depression and anxiety disorders, Ebixa for the treatment of Alzheimer’s disease, Azilect for the treatment of Parkinson’s disease, Xenazine for the treatment of Huntington’s disease and Sabril for the treatment of epilepsy, among others. The Company operates through a number of subsidiaries, such as Lundbeck SAS, Lundbeck GmbH, SIA Lundbeck Latvia and Lundbeck LLC.
Employees
5,000
Date Price Change Volume
08/26/08 DKK 43.85 +0.92% 47,409
07/26/07 DKK 43.45 +0.58% 33,353
06/26/06 DKK 43.20 +1.41% 59,317
05/26/05 DKK 42.60 +2.16% 38,048
02/26/02 DKK 41.70 +1.21% 15,024
Trader
Investor
Global
Quality
ESG MSCI
-
Ratings Surperformance© - Lundbeck
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
46.12DKK
Average target price
49.19DKK
Spread / Average Target
+6.66%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Lundbeck